AbbVie Ventures

AbbVie Ventures is the corporate strategic venture capital arm of AbbVie, the North Chicago based biopharmaceutical company. AbbVie describes the unit as investing since 2009 in transformational scientific opportunities aligned with its core R&D interests, with the stated aim of gaining access to next-generation science and building relationships with proven and emerging scientific leaders. The unit sits alongside AbbVie's Discovery Research and Search and Evaluation groups and connects them to science happening outside the company.

The unit focuses exclusively on novel therapeutics at the discovery and preclinical stages. Its current focus areas, per AbbVie's site, are oncology, immunology, neuroscience, obesity and aesthetics, and its portfolio page also lists eye care, an area AbbVie entered through the Allergan acquisition. AbbVie says the active portfolio comprises more than 30 companies in the US and Europe and that it targets six to eight new investments a year, predominantly at Seed or Series A, with the ability to create companies and to lead or co-lead syndicates. A 2024 AbbVie partner feature in Nature Biopharma Dealmakers described the unit as investing from company creation through Series B. The investing team is spread across Cambridge (MA), San Francisco, Oxford, Ludwigshafen and Shanghai.

The distinctive offer is access to AbbVie's internal expertise across drug discovery, development, regulatory, manufacturing and commercialization, which the unit says it extends to portfolio companies from diligence onward. It also uses senior venture partners and scientists in residence drawn from AbbVie R&D. In the same 2024 feature, AbbVie reported that 10 portfolio companies went public between 2020 and 2024 and 11 were acquired. Former investments listed on its portfolio page include companies acquired by Gilead, Merck, Lilly, Amgen, Sanofi, Novartis and Otsuka. Active holdings include DISCO Pharmaceuticals, Xilio Therapeutics and Umoja Biopharma.